CALCIUM FUMARATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C4H2O4.Ca
Molecular Weight	154.134
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++].[O-]C(=O)\C=C\C([O-])=O

InChI

InChIKey=HDRTWMBOUSPQON-TYYBGVCCSA-L

InChI=1S/C4H4O4.Ca/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;

HIDE SMILES / InChI

Molecular Formula	C4H2O4
Molecular Weight	114.0563
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18390439 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.350&SearchTerm=fumaric%20acid | http://www.bartek.ca/calcium_fumarate.html

Calcium Fumarate is a calcium salt of fumaric acid, it can be used as a food supplement. Calcium Fumarate may be used to treat conditions caused by low Calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough Calcium (e.g., women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone). Calcium Fumarate is classified by the FDA as a dietary and nutritional additive (21CFR§172.350) and has been used for many years.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypocalcemia 75 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18390439 http://www.bartek.ca/pdfs/BulletinsSoluCal/SOLUCALift.pdf https://www.ncbi.nlm.nih.gov/pubmed/12806828	Primary		Approved 8429	Calcium Fumarate Approved Use Indication: For treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin D deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, in the treatment of intestinal malabsorption, and to replenish electrolytes.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

According to the treatment schedule, after a 12 hours overnight fast, each subject was given tablets containing 675mg calcium in total either in the form of calcium gluconate or calcium fumarate orally with a glass of water. Standard breakfast was served after the 4th hour.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:24:26 UTC 2023` Edited by `admin` on `Fri Dec 15 15:24:26 UTC 2023`
Record UNII	VD906S8V0I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM FUMARATE

Systematic Name

English

CALCIUM (E)-BUT-2-ENEDIOATE

Systematic Name

English

E367

Common Name

English

FULAXAN

Common Name

English

2-BUTENEDIOIC ACID (2E)-, CALCIUM SALT

Common Name

English

2-BUTENEDIOIC ACID (E)-, CALCIUM SALT

Systematic Name

English

Calcium fumarate [WHO-DD]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 172.350